苯酚,4-(5-氨基戊基)- | 154585-03-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 中文名称: 苯酚,4-(5-氨基戊基)-
• 英文名称: 5-(4-Hydroxyphenyl)pentyl amine
• 英文别名: 4-(5-Aminopentyl)phenol
• CAS: 154585-03-2
• 化学式: C₁₁H₁₇NO
• 分子量: 179.262
• InChiKey: XBBKSRBELVRMQH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  13
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  46.2
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  methyl 3,5-diamino-6-chloropyrazine-2-carbonylcarbamimidothioate hydroiodic acid salt 、 苯酚,4-(5-氨基戊基)- 在 乙醚 、 乙酸乙酯 、 盐酸 、 solution 、 水 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 2.33h， 以to give 22 (183 mg, 39%) as a yellow solid的产率得到5-(4-Hydroxyphenyl)pentylamidino-3,5-diamino-6-chloropyrazinecarboxamide hydrochloride
  参考文献：
  名称：

  Phenolic guanidine sodium channel blockers

  摘要：

  本发明涉及由公式(I)表示的化合物： 其中R3和R4中至少一个是由公式(A)表示的基团： 其中结构变量在此定义。这些化合物对于阻断钠通道是有用的。

  公开号：

  US06858614B2

文献信息

• Sodium channel blockers
  申请人：CYFI, INC.

  公开号：US20030195160A1

  公开（公告）日：2003-10-16

  The present invention relates to sodium channel blockers. The present invention also relates to a variety of methods of treatment using these sodium channel blockers.

  本发明涉及钠通道阻滞剂。本发明还涉及使用这些钠通道阻滞剂进行治疗的各种方法。
• Methods of using phenolic guanidine sodium channel blockers
  申请人：PARION SCIENCES, Inc.

  公开号：US20040198744A1

  公开（公告）日：2004-10-07

  The present invention relates to sodium channel blockers. The present invention also relates to a variety of methods of treatment using these sodium channel blockers.

  本发明涉及钠通道阻滞剂。本发明还涉及使用这些钠通道阻滞剂的各种治疗方法。
• Design, Synthesis, and Structure−Activity Relationships of Novel 2-Substituted Pyrazinoylguanidine Epithelial Sodium Channel Blockers:  Drugs for Cystic Fibrosis and Chronic Bronchitis
  作者：Andrew J. Hirsh、Bruce F. Molino、Jianzhong Zhang、Nadezhda Astakhova、William B. Geiss、Bruce J. Sargent、Brian D. Swenson、Alexander Usyatinsky、Michael J. Wyle、Richard C. Boucher、Rick T. Smith、Andra Zamurs、M. Ross Johnson

  DOI：10.1021/jm051134w

  日期：2006.7.1

  Amiloride (1), the prototypical epithelial sodium channel (ENaC) blocker, has been administered with limited success as aerosol therapy for improving pulmonary function in patients with the genetic disorder cystic fibrosis. This study was conducted to synthesize and identify more potent, less reversible ENaC blockers, targeted for aerosol therapy and possessing minimal systemic renal activity. A series of novel 2-substituted acylguanidine analogues of amiloride were synthesized and evaluated for potency and reversibility on bronchial ENaC. All compounds tested were more potent and less reversible at blocking sodium-dependent shortcircuit current than amiloride. Compounds 30-34 showed the greatest potency on ENaC with IC50 values below 10 nM. A regioselective difference in potency was found (compounds 30, 39, and 40), whereas no stereospecific (compounds 33, 34) difference in potency on ENaC was displayed. Lead compound 32 was 102-fold more potent and 5-fold less reversible than amiloride and displayed the lowest IC50 value ever reported for an ENaC blocker.
• SODIUM CHANNEL BLOCKERS
  申请人：Johnson, Michael R.

  公开号：EP1485359A2

  公开（公告）日：2004-12-15
• EP1485359A4
  申请人：——

  公开号：EP1485359A4

  公开（公告）日：2006-03-22